BLRX BioLineRx Ltd
Company Analysis
Latest News
🟢 BioLineRx is trading 9.8% up in pre-market
BioLineRx is trading +9.80% at $2.80 after no clear company-specific catalyst was identified for September 10, 2026. - The latest available company update...
🔴 BioLineRx is trading 9.02% down in after-hours trading with no new company-specific catalyst identified
BioLineRx is trading 9.02% down at $2.32 after-hours on September 9, 2026, versus the regular-session close of $2.55; no major company announcement, earnings...
🔴 BioLineRx is trading 5.98% down in after-hours trading after Q2 net loss widened
BioLineRx is trading 5.98% down now at $2.51 after investors continued digesting its August 31, 2026, second-quarter results. - Revenue was $0.3 million,...
🔴 BioLineRx is trading 8.76% down in pre-market after Q2 revenue missed expectations and losses widened
BioLineRx is trading 8.76% down in pre-market at $2.50 as investors continue digesting its August 31, 2026 second-quarter results, which showed revenue below...
🔴 BioLineRx is trading 6.88% down today after weak Q2 results and dilution pressure
BioLineRx is trading 6.88% down at $2.57 after weak Q2 financial results and financing-related dilution pressure. - August 31 earnings showed Q2 royalty...
🔴 BioLineRx is trading 6.81% down in after-hours trading after Q2 revenue missed expectations
BioLineRx is trading at $2.57 (-6.81%) in after-hours trading after second-quarter revenue missed expectations and APHEXDA royalty income remained weak. • The...
🔴 BioLineRx is trading 6.5% down today as biotech falls 4.24%
BioLineRx is trading 6.5% down at $2.62 amid broad risk-off selling, with biotech down 4.24% and the Nasdaq down 1.00%. - September 1, 2026 weakness followed...
🔴 BioLineRx is trading 6.79% down in pre-market after second-quarter revenue missed estimates
BioLineRx is trading 6.79% down in pre-market at $2.61 after second-quarter revenue of $0.3 million missed the $0.5 million analyst estimate. - In its August...
🟢 BioLineRx is trading 11.44% up today amid GLIX1 clinical expansion
BioLineRx is trading at $2.85 (+11.44%), with investors possibly responding to GLIX1’s clinical expansion. - Reported $0.3 million in second-quarter revenue,...
🟢 BioLineRx is trading 5.65% up today after accelerated GLIX1 development
BioLineRx is trading at $2.70 (+5.65%) after its August 31, 2026 earnings release, as GLIX1 progress and financing may be outweighing weaker royalty...
BioLineRx reports second quarter revenue of $0.3M missing estimates amid GLIX1 clinical expansion
BioLineRx reported second quarter 2026 revenue of $0.3 million, falling short of analyst expectations of $0.5 million. The company reported a net loss...
BioLineRx Pairs Earnings Day With a Cash Lifeline — But at $3.75 Million, Is It Enough to Keep the Lights On?
Shares of BioLineRx surged 9.6% to $2.85 in early trading on August 31, as investors digested a twin catalyst: the company's second-quarter earnings release...
🟢 BioLineRx is trading 9.6% up in pre-market ahead of Q2 results
BioLineRx is trading 9.6% up at $2.85 after closing at $2.60 on August 28, 2026, ahead of scheduled second-quarter results. - Results are due before the...
BioLineRx Ltd Q2 2026 Earnings Preview: What Analysts Expect on August 31, 2026
For the Q2 2026 reporting period, BioLineRx is expected to post revenue of $0.50 million and a break-even EPS of $0.00, as the stock trades at $2.60 against a...
🔴 BioLineRx is trading 5% down today after announcing a $3.75 million financing
BioLineRx is trading 5.04% down now at $2.64 after announcing a $3.75 million registered direct offering and concurrent private placement on August 28,...
🔴 BioLineRx is trading 20.14% down in pre-market after no company-specific announcement was identified
BioLineRx is trading at $2.22, down -20.14%, after no company-specific announcement was identified for August 28, 2026. • The latest company release announced...
🟢 BioLineRx is trading 5.56% up today as broader markets strengthen
BioLineRx is trading 5.56% up now at $2.85 as broader markets strengthen. - Nasdaq is up 1.60% and S&P 500 is up 0.77%. - No clear company-specific...
🔴 BioLineRx is trading 5.69% down today — No clear company-specific catalyst identified
BioLineRx is trading 5.69% down at $2.65, with no clear company-specific catalyst identified for the August 26, 2026 decline. - BioLineRx announced on August...
🟢 BioLineRx is trading 7.84% up today as XBI gains 2.06%
BioLineRx is trading 7.84% up at $3.03, benefiting primarily from a stronger biotechnology sector. - XBI is up 2.06% during the regular session. - No new...
BioLineRx Ltd Q2 2026 Earnings Preview: What Analysts Expect on August 27, 2026
BioLineRx is projected to report Q2 2026 consensus revenue of $0.50 million and a break-even EPS of $0.00, with its current $2.85 share price trading well...